BioHaven Presents: Dr. John LaMattina – The Biopharmaceutical Industry’s Challenges in Drug Pricing
A Discussion of Drug Pricing Transparency
Cantor Colburn is pleased to sponsor a CURE BioHaven event, "The Biopharmaceutical Industry’s Challenges in Drug Pricing" with Dr. John LaMattina, about drug pricing transparency.
Cantor Colburn is a member of CURE, Connecticut’s bioscience network. Dr. John LaMattina is currently a Senior Partner at PureTech Health, and is the former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS.
Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis and Vedanta Biosciences.